Loading stock data…
ALT
$2.66-0.07 (-2.56%)
After Hours$2.66+0.00 (+0.00%)· Last close Jun 9
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Altimmune, Inc. in the Healthcare sector is trading at $2.66. Wall Street consensus targets $16.06 (9 analysts), implying a +503.6% move over the next 12 months. The stock is currently near its 52-week low of $2.56, remaining 32.1% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +503.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$2.66
Potential Downside
0%
Whystock Fair Value$2.66
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Buy
Mean target$16.06+503.6%
Range$2.50 – $28.00
Fundamentals
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-32.07%
Volume
Today's trading volume
3.32M
Recent News
ALT and the Rise of Dual Agonists Targeting Liver Disease
Altimmune's dual-agonist pemvidutide faces key 2026 tests in MASH and alcohol-related diseases that could validate its multi-pathway liver strategy.
ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup
Altimmune is betting on pemvidutide across MASH and alcohol-related liver diseases, with key 2026 data and a planned Phase III launch shaping its path.
Is Altimmune Worth Buying Ahead of 2026 Catalysts?
ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set to test pemvidutide's multi-indication story.
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial
Altimmune (NASDAQ:ALT) executives said the company is preparing to begin enrolling patients in the second half of the year for a Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis, or MASH, while also awaiting data from related alcohol-associated liver disease programs.
Here's Why You Should Add Altimmune Stock to Your Portfolio Now
ALT advances pemvidutide in MASH, AUD and ALD, with phase III plans and promising liver disease data fueling investor focus.